Therapeutic approach against intimal hyperplasia of vein grafts through endothelial nitric oxide synthase/nitric oxide (eNOS/NO) and the Rho/Rho-kinase pathway

Keyphrases

• Nitric Oxide 100%
• Therapeutic Approaches 100%
• Rho Kinase 100%
• Intimal Hyperplasia 100%
• Endothelial Nitric Oxide Synthase (eNOS) 100%
• Vein Graft 100%
• Cell Proliferation 33%
• Rho Kinase Inhibitor 33%
• Statins 33%
• Intimal Thickening 33%
• Gene Transfer 16%
• Therapeutic Modalities 16%
• Negatively Regulate 16%
• Oral Administration 16%
• Arginine 16%
• Beta-blockers 16%
• Vascular Smooth muscle Cells 16%
• Pathophysiological Changes 16%
• Graft Failure 16%
• Causes of Change 16%
• Late Graft Failure 16%
• Autologous Vein Graft 16%
• Vasorelaxation 16%

Medicine and Dentistry

• Rho Kinase 100%
• Intimal Hyperplasia 100%
• Endothelial Nitric Oxide Synthase 100%
• Nitric Oxide 100%
• Vein Graft 100%
• Cell Proliferation 33%
• Artery Intima Proliferation 33%
• Statin 33%
• Graft Failure 33%
• Therapeutic Modality 16%
• Rho Kinase Inhibitor 16%
• Oral Drug Administration 16%
• Gene Transfer 16%
• Beta Adrenergic Receptor Blocking Agent 16%
• Vasodilatation 16%
• Vascular Smooth Muscle Cell 16%
• Arginine 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Nitric Oxide 100%
• Rho Kinase 100%
• Hyperplasia 100%
• Endothelial Nitric Oxide Synthase 100%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 33%
• Graft Failure 33%
• Artery Intima Proliferation 33%
• Arginine 16%
• Rho Kinase Inhibitor 16%
• Beta Adrenergic Receptor Blocking Agent 16%